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matched and analyzed to see if there any trend and relation between the num-
ber of drugs added in the NHF and the percentage of deaths listed for each dis-
ease. Results: The NHF has drugs for every disease evaluated. In the period 
analyzed, the number of drugs for DM has increased from 18 to 24. In the case of 
IHD, the number has also grown from 20 to 32. For CD there has been also an addition 
from 10 to 13. The drugs for ALD is the same in each year (only one drug). At last, 
for COPD the number has change from 35 to 36 drugs. Comparing with the number 
of deaths, the IHD is the disease with the biggest increased of deaths (22%), then 
the DM with 12%, COPD 11%, ALD 4%, and CD 3%. ConClusions: Although there 
have been added new drugs prescribed for the diseases that caused the deaths of 
most population in the NHF, this quantity is not comparable with the growing of 
deaths observed in each disease.
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objeCtives: As reported by the Centers for Disease Control and Prevention (CDC) 
more than half of adults with high blood cholesterol level did not receive any treat-
ment. Untreated high blood cholesterol can lead to coronary heart diseases. The 
primary objective of this study is to describe and contrast the socioeconomic factors 
between treated and untreated patients with hyperlipidemia. Secondary objective is 
to compare prescribed medicines expenditures between the two groups. Methods: 
This study conducted cross-sectional secondary data analyses using 2012 Medical 
Expenditures Panel Survey (MEPS). Study subjects consisted of US civilian, non-
institutionalized adults diagnosed with high blood cholesterol. Series of statistical 
comparisons on socioeconomic factors, and prescribed medicines expenditures and 
utilizations between hyperlipidemia patients with any FDA-approved lipid lowering 
agent and hyperlipidemia patients without lipid lowering agents. The Andersen 
Behavioral Model was applied to define the socioeconomic factors. SAS 9.3 statistical 
software was used for all analyses including sample weights and standard errors 
adjustments. Results: Approximately 19 million patients had high blood choles-
terol related events in 2012. The average age of treatment group was older than the 
average age of no-treatment group, 64 and 62 years old respectively, (p< 0.001). 95% 
of hyperlipidemia patients with high income had treatment, on the contrary, 93% 
of hyperlipidemia patients with near poor income had treatment. The average total 
prescription expenditures for patients with treatment was higher than patients 
without treatment, $3032 and $2509 respectively, (p< 0.001). ConClusions: The 
study findings showed substantial number of hyperlipidemia patients without 
treatment. Also there were some socioeconomic differences between treatment 
group and no-treatment group. Further research is recommended to understand 
the complex role of socioeconomic factors in hyperlipidemia therapy to make more 
effective policies and programs designed to improve treatment for one of the major 
chronic conditions in the United States.
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objeCtives: To analyze the use of statins in 90 days after hemodialysis among the 
prior-users. Methods: This retrospective cohort study used the 1997-2008 National 
Health Insurance Research Data to analyze the use of statins among prior users 
aged 20 years or older after they started maintenance hemodialysis. These prior 
users were prescribed with statins at least once in 180 days prior to hemodialysis. 
Discontinuation of statin prescription was defined when there was no prescrip-
tion records in the following 90 days, and the date of discontinuation was coded 
as the last date of prescription plus medication period. We used Cox proportional 
hazard model to examine the potential factors attributable to the discontinuation 
of statin prescription. We also analyze the pattern of re-use of statins after one 
year. Results: Among 8982 statin users, 2079 patients continued to use statins 
after hemodialysis. In 90 days after hemodialysis, the average medication days 
among the continued users was 65.8 days. Among the discontinued users, 65% 
stopped using statins in the 90 days before hemodialysis; 8.7% of them started 
using statins in the first 6 months and 19% started in the first year again. Analysis 
of the Cox proportional hazard model showed that being male(HR 1.10, 95% CI 1.05, 
1.15) and no statin prescription in 90 days before hemodialysis(HR 1.78ï¿½, 95% 
CI 1.68, 1.87) were attributable to the discontinuation of statins in 90 days after 
hemodialysis; those with coronary heart disease(HR 0.93ï¿½, 95% CI 0.89, 0.98) and 
peripheral vascular disease(HR 0.87ï¿½, 95% CI 0.79, 0.96) tended to continue using 
statins. ConClusions: Most statin users stopped using statins after hemodialysis. 
In fact, most of them stopped using statins in the 90 days before hemodialysis. 
Subjects who were female and with medical history of cardiovascular diseases 
or peripheral vascular disease were more likely to continue using of statins after 
hemodialysis.
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objeCtives: Cardiovascular diseases (CVD) are the major health problem in con-
temporary world, particularly in developing countries. The impact of the costs 
of Agents acting on RAS to the healthcare budgets is relatively high. It is impor-
tant to establish the use of cheaper generic and to reduce the healthcare costs. 
The aim of our study was to identify and analyze changes in the usage of these 
up and significant reduction on medications consumption. Patients who increased 
BMI during the wait list presented lower rates of comorbidities resolution compared 
to patients who maintained or reduced their BMI in the wait list. Based on the out-
comes presented, bariatric surgery is a procedure that can help the Brazilian health 
system to treat obesity and its co-morbidities
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objeCtives: The efficacy of warfarin for reducing stroke risk is influenced by its 
time-in-therapeutic range (TTR, i.e. time patients spend having an international 
normalized prothrombin time ratio, INR= 2-3). This study evaluated warfarin TTRs 
among nonvalvular atrial fibrillation (NVAF) patients treated in an integrated 
healthcare delivery system (IDHS) setting. Methods: Patients with NVAF, war-
farin therapy, and INR measurements were identified from an electronic medical 
record database (1/1/2004-8/31/2013). NVAF patients were required to have ≥ 6 INR 
test values to ensure chronic warfarin therapy. Warfarin TTRs were determined by 
the modified Rosendaal method. INR values collected during hospitalization stays 
were not included in the TTR calculation, since they may not be indicative of poor 
INR control. Patient characteristics during a 12-month follow-up period after the 
first INR test were evaluated. Results: Among the NVAF study population, greater 
than half (54%, n= 1,595) had a low TTR (< 60%) and 46% (n= 1,356) had a high TTR 
(≥ 60%). Mean ages of patients with low and high TTR were 71.1 and 72.2 years, 
respectively. Charlson Comorbidity Index (2.9 vs. 2.3, p< 0.001) and CHADS2 (2.2 
vs. 2.0, p< 0.001) scores were higher for NVAF patients with low TTR vs. high TTR. 
Among NVAF patients with low TTR, 79% had a warfarin TTR < 55% and 21% had a 
TTR of 55-60% during the follow-up period. Among NVAF patients with high TTR, 
24%, 41%, and 35% had warfarin TTRs of 60-64%, of 65-74%, and ≥ 75%, respectively 
during the follow-up period. Among NVAF patients with low and high TTR, 45% 
and 73% of them spent time in the warfarin therapeutic range (INR between 2-3), 
respectively. ConClusions: Based on a conservative approach to evaluate the 
warfarin TTR, our results indicate that it still remains very challenging in a con-
temporary real-world setting to achieve consistently good levels for the majority 
of our NVAF patients.
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objeCtives: A key goal for managed care organizations is to improve patient 
health outcomes and reduce costs. One strategy involves increasing medication 
adherence among patients with chronic diseases. The Kentucky Department for 
Medicaid Services contracted with three managed care organizations in November 
2011 to transition the state’s traditional fee-for-service Medicaid patients into 
capitated managed care. The purpose of this study is to determine differences in 
medication adherence before and after the switch from fee-for-service to managed 
care for Medicaid patients in Kentucky with essential hypertension between 2010 
and 2012. Methods: The retrospective cohort study sample will be drawn from 
a database of Kentucky Medicaid patient (age 18-64) medical and prescription 
claims between 2010 and 2012. The University of Kentucky Internal Review Board 
approved the study. The study will include descriptive statistics of the medica-
tion possession ratio (MPR) and control variables including patient demographics, 
type of antihypertensive, and comorbidities. Bivariate analyses will measure the 
effect of each variable on the change in MPR as a result of the switch. Multivariate 
analysis will be a difference-in-difference regression model, measuring the pre and 
post differences in MPR due to the introduction of managed care. Results: Initial 
data collected indicate that average MPR decreased by about 13 percentage points, 
regardless of medication class, after Medicaid managed care in Kentucky took 
effect, with other factors held constant. A 13-percentage point decrease in MPR 
corresponds to about 45 fewer days of medication possession. ConClusions: 
Results are preliminary, but indicate a need to address the efficacy of Medicaid 
managed care on adherence to antihypertensives in Kentucky. Additional studies 
should be conducted with data from 2013 to ensure confounding due to transi-
tional issues is eliminated. Future studies will examine the effect of Medicaid 
managed care on adherence in hyperlipidemia, diabetes, asthma, and mental 
health disorders.
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objeCtives: The aim of this work is to demonstrate if the National Health 
Formulary (NHF) has included drugs related to the principal causes of death in the 
last 5 years (Diabetes Mellitus (DM), Ischemic Heart Diseases (IHD), Cerebrovascular 
Diseases (CD), Alcoholic Liver Diseases (ALD) and Chronic Obstructive Pulmonary 
Disease (COPD)), and if the number of the drugs added each year is in accordance 
with the increase number of deaths per disease. Methods: A search in the National 
Institute of Statistics and Geography and the National System of Information on 
Health was done, from 2009 to 2013, related to the 5 principal causes of death in 
Mexico. Then, there were counted and analyzed the number of drugs prescribed 
for each disease studied in the last 5 NHF editions. Finally, all data obtained was 
